CAN1012 in Pre-Malignant DCIS and LCIS

StatusRecruiting
PhasePhase 1
Started

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Track this trial
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Recruitment opened Show 4 more changesShow less
    • Lead sponsor: Providence Health & Services to Providence Health & Services
    • Start date changed from estimate of Aug 2026 to Sep 16, 2026
    • Eligibility criteria expanded, about 23 words
    • Site details revised
  2. Start date: May 2026 to Aug 2026v3
  3. Enrollment reduced: 60 → 24 participantsv2 Show 4 more changesShow less
    • Trial arms changed: 3 → 4
    • Interventions: CAN1012 (.2 mL) (Drug), CAN1012 (.4 mL) (Drug) to CAN1012 (Drug)
    • Study title revised
    • Eligibility criteria expanded, about 5 words
  4. Study First Submitted
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
This is a Phase I/Ib study evaluating CAN1012 in patients with ductal carcinoma in situ and lobular carcinoma in situ.
Trial Details
NCT Number NCT07408856
Lead Sponsor Providence Health & Services
Collaborators: CanWell Pharma Inc.
Conditions
(from sponsor)		 Ductal Carcinoma in Situ, Lobular Carcinoma in Situ
Related terms Breast Carcinoma In Situ, Carcinoma, Intraductal, Noninfiltrating
Enrollment 24 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov